;

Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Finance > Biotech firm Galapagos to wind down cell therapy business

Finance

Biotech firm Galapagos to wind down cell therapy business

Published by Global Banking and Finance Review

Posted on October 21, 2025

Featured image for article about Finance

AMSTERDAM (Reuters) -Biotechnology firm Galapagos said on Tuesday it would wind down its cell therapy business after attempts to sell it were unsuccessful, affecting 365 jobs in Europe, China and the U.S.

The Amsterdam-listed company said it had received several non-binding offers since it began mulling options for its cell therapy business in May, but had concluded that none of those were viable proposals.

Galapagos said it now made more sense to gradually end the cell therapy business and use the capital to build a pipeline of new therapies.

Shares in the company were down 14% in early trading after its announcement.

(Reporting by Bart Meijer; Editing by Jan Harvey)

More from Finance

Explore more articles in the Finance category

Warner Bros Discovery board rejects rival bid from Paramount

UK tells Abramovich to give Chelsea sale cash to Ukraine or face court

WTO chair rules out reform deal at next major meeting, document shows

EU Parliament approves phase out of Russian gas imports

Putin says Russia will take more land in Ukraine if Europe sinks peace moves

Italy's Meloni says it's still 'premature' to sign EU-Mercosur trade deal

Russian attack on Ukraine's Zaporizhzhia injures 26, governor says

UK stocks rebound on banking gains ahead of BoE rate cut call

Decline in UK industrial orders eases slightly, CBI says

Serco sees profit ahead of market view through 2026; CFO to retire next year

Analysis-Crypto investors show caution, shift to new strategies after crash

Growth in UK house prices and private rents slows

View All Finance Posts